
|Articles|December 14, 2022
Readying Biologics for Commercialization
Author(s)Thermo Fisher Scientific
Given the risks and opportunities inherent in drug development, choosing the right late-phase strategy to optimize timelines and capacity, while remaining flexible enough for changing market conditions, presents a significant challenge to companies developing and commercializing biopharmaceutical products. This piece highlights new technologies and strategies to reduce risk and execute consistently.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
2
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
3
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
4
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
5
